Literature DB >> 9223512

Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation.

Y Takeuchi1, S H Liong, P D Bieniasz, U Jäger, C D Porter, T Friedman, M O McClure, R A Weiss.   

Abstract

Vesicular stomatitis virus, human immunodeficiency virus type 2, and human foamy virus, which were produced by cell lines expressing galactosyl(alpha1-3)galactosyl (alphaGal) sugars, were found to be less stable in human serum than those from alphaGal-negative cells, indicating that galactosyl(alpha1-3)galactosylation sensitizes these viruses as well as mammalian type C oncoviruses (Rother et al., J. Exp. Med. 182:1345-1355, 1995; Takeuchi et al., Nature (London) 379:85-88, 1996) to complement killing via natural anti-alphaGal antibodies. Thus, virus killing mediated by anti-alphaGal antibodies may play a role as a barrier to animal-to-human infection of various enveloped viruses. Virus vectors for human in vivo gene therapy based on the viruses mentioned above should be produced from alphaGal-negative cells.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9223512      PMCID： PMC191878     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  41 in total

1.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Human foamy virus: further characterization, seroepidemiology, and relationship to chimpanzee foamy viruses.

Authors:  P Brown; G Nemo; D C Gajdusek
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

3.  Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.

Authors:  Y Takeuchi; F L Cosset; P J Lachmann; H Okada; R A Weiss; M K Collins
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 4.  Human gene therapy comes of age.

Authors:  A D Miller
Journal:  Nature       Date:  1992-06-11       Impact factor: 49.962

5.  One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody.

Authors:  U Galili; F Anaraki; A Thall; C Hill-Black; M Radic
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

6.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.

Authors:  J C Burns; T Friedmann; W Driever; M Burrascano; J K Yee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

7.  A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes.

Authors:  J K Yee; A Miyanohara; P LaPorte; K Bouic; J C Burns; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Reactivity of primate sera to foamy virus Gag and Bet proteins.

Authors:  H Hahn; G Baunach; S Bräutigam; A Mergia; D Neumann-Haefelin; M D Daniel; M O McClure; A Rethwilm
Journal:  J Gen Virol       Date:  1994-10       Impact factor: 3.891

9.  Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys.

Authors:  U Galili; K Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Human immunodeficiency virus infection of cells arrested in the cell cycle.

Authors:  P Lewis; M Hensel; M Emerman
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598
View more
  16 in total

Review 1.  Xenotransplantation--2000.

Authors:  M J Goddard; J E Foweraker; J Wallwork
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

2.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 3.  Cross-species virus transmission and the emergence of new epidemic diseases.

Authors:  Colin R Parrish; Edward C Holmes; David M Morens; Eun-Chung Park; Donald S Burke; Charles H Calisher; Catherine A Laughlin; Linda J Saif; Peter Daszak
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

4.  A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines.

Authors:  T Arai; K Matsumoto; K Saitoh; M Ui; T Ito; M Murakami; Y Kanegae; I Saito; F L Cosset; Y Takeuchi; H Iba
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Mapping full-length porcine endogenous retroviruses in a large white pig.

Authors:  C Herring; G Quinn; R Bower; N Parsons; N A Logan; A Brawley; K Elsome; A Whittam; X M Fernandez-Suarez; D Cunningham; D Onions; G Langford; L Scobie
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 6.  Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology.

Authors:  Lucile Warter; Ramapraba Appanna; Katja Fink
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 7.  Glycan Reactive Natural Antibodies and Viral Immunity.

Authors:  J Stewart New; R Glenn King; John F Kearney
Journal:  Viral Immunol       Date:  2019-12-17       Impact factor: 2.257

8.  Study of full-length porcine endogenous retrovirus genomes with envelope gene polymorphism in a specific-pathogen-free Large White swine herd.

Authors:  S Bösch; C Arnauld; A Jestin
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64.

Authors:  Yuuki Kaname; Hideki Tani; Chikako Kataoka; Mai Shiokawa; Shuhei Taguwa; Takayuki Abe; Kohji Moriishi; Taroh Kinoshita; Yoshiharu Matsuura
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Authors:  Saema Magre; Yasuhiro Takeuchi; Gillian Langford; Andrew Richards; Clive Patience; Robin Weiss
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.